SLC5A2 and chronic obstructive pulmonary disease: Pradhan et al. have demonstrated that GLP-1 receptor agonists and SGLT-2 inhibitors were capable of reducing severe exacerbations compared to sulfonylureas in patients diagnosed with COPD.